Cargando…

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis

Autoimmune diabetes is a rare but severe endocrine toxicity induced by immune checkpoint inhibitor (ICI) treatment. It is unclear if ICI causes selective islet toxicity or non-selective pancreas toxicity. We analyzed 11 patients treated with ICI who developed ICI-related autoimmune diabetes. Eight p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Amy L., Wang, Fang, Chang, Lee-Shing, McDonnell, Marie E., Min, Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076788/ https://www.ncbi.nlm.nih.gov/pubmed/33927691 http://dx.doi.org/10.3389/fendo.2021.620522

Ejemplares similares

SUN-LB024 Elevation in Morning Glucose Level May Be a Signal for the Development of Immune Checkpoint Inhibitor (ICPi) Induced Autoimmune Diabetes Insulin
por: Zhang, Amy, et al.
Publicado: (2019)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Wu, Linda, et al.
Publicado: (2021)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease
por: Aslaksen, Sigrid, et al.
Publicado: (2019)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review
por: Hong, A Ram, et al.
Publicado: (2020)

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
por: Hilder, Robin, et al.
Publicado: (2023)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Mechanisms and therapeutic strategies of immune checkpoint molecules and regulators in type 1 diabetes
por: Ding, Jia-Tong, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
por: Di Molfetta, Sergio, et al.
Publicado: (2021)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2023)

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review
por: Gao, Yue, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
por: Zhan, Ling, et al.
Publicado: (2021)

A Case of Immune Checkpoint Inhibitor Induced Autoimmune Diabetes
por: Thambuluru, Sirisha Reddy
Publicado: (2021)

Coexistence of Autoimmune Thyroiditis and Juvenile Idiopathic Arthritis
por: Sapountzi, Evdoxia, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects
por: Iwamoto, Yuichiro, et al.
Publicado: (2023)

Therapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells
por: Jo, Sugyeong, et al.
Publicado: (2021)

Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM
por: Zhang, Wenjing, et al.
Publicado: (2023)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
por: Burnett, Deborah L., et al.
Publicado: (2023)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

miRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes
por: Scherm, Martin G., et al.
Publicado: (2020)

A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011–2021
por: Zhang, Hongyi, et al.
Publicado: (2023)

Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
por: Lee, Hanna J., et al.
Publicado: (2023)

The Coexistence of Autoimmune Pancreatitis and Crohn’s Disease in an Adolescent Case
por: Dogan, Guzide, et al.
Publicado: (2020)

Fatal Immune Checkpoint Inhibitor-related Pancreatitis
por: Ueno, Masayuki, et al.
Publicado: (2021)

Inflammation, oxidative stress and mitochondrial dysfunction in the progression of type II diabetes mellitus with coexisting hypertension
por: Yousef, Hibba, et al.
Publicado: (2023)

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
por: Duong, Sophie L., et al.
Publicado: (2022)

Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases
por: Maeda, Osamu
Publicado: (2023)

Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes
por: Colli, Maikel L., et al.
Publicado: (2020)

Early Detection of Immune-Mediated Hypophysitis With Use of Checkpoint Inhibitor Immunotherapy
por: Yossef, Kristena, et al.
Publicado: (2022)

Autoimmune reaction against pancreatic beta cells in children and adolescents with simple obesity
por: Chylińska-Frątczak, Aneta, et al.
Publicado: (2022)

Editorial: Latent Autoimmune Diabetes in Adults (LADA)
por: Leslie, Richard David
Publicado: (2022)

Environmental Triggering of Type 1 Diabetes Autoimmunity
por: Houeiss, Pamela, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System
por: Lu, Difei, et al.
Publicado: (2022)

Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis
por: Liang, Xueyan, et al.
Publicado: (2023)

Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma
por: Luo, Yi, et al.
Publicado: (2022)

Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency
por: Katakura, Yukino, et al.
Publicado: (2021)

Transient Thyroiditis Followed by Exacerbation of Hypothyroidism After Immune Checkpoint Inhibitor Therapy (Nivolumab and Ipilimumab) in a Patient With Pre-existing Autoimmune Hypothyroidism: A Case Report
por: Hayakawa, Guy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t7scrgiod71jnbvfenu0bbl9rm